Racks Biotech

pipelines & approvals

Live · refreshes automatically

Top story AstraZeneca made a $10 billion offer for Rhythm Pharmaceuticals, WSJ reports

The reported bid would be a sizable bolt-on for AstraZeneca's rare disease and obesity pipeline and follows a wave of large pharma M&A.

full coverage →m&apharmarare-disease
Novo Nordisk hikes 2026 outlook again as Wegovy pill rollout accelerates

The third guidance lift reflects strong oral GLP-1 demand, with Novo also eyeing a US launch of the combination drug Cagrisema.

full coverage →glp-1earningsobesity
Eli Lilly widens GLP-1 lead over Novo Nordisk with nearly double the sales

Lilly's incretin franchise continues to outpace Novo Nordisk in the market for obesity and diabetes drugs.

full coverage →glp-1obesityearnings
Pfizer raises 2026 forecasts as Eliquis and cancer drugs offset falling Covid sales

Newer products are filling the revenue gap left by declining demand for Pfizer's Covid franchise.

full coverage →earningspharma
Madrigal's former clinical development head files whistleblower suit alleging Rezdiffra safety cover-up

The lawsuit raises questions about safety disclosures for Madrigal's liver disease drug, its key commercial asset.

full coverage →legalsafetyliver-disease
Biopharma stocks likely to climb higher after 'blue wave,' analysts say

Analysts expect a friendlier policy backdrop for drugmakers following the election results.

full coverage →marketspolicy
Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment

The label expansion moves the BTK inhibitor into frontline use for chronic lymphocytic leukemia and small lymphocytic lymphoma.

full coverage →fdaoncologyapproval
Celltrion says 4-hormone obesity drug beats Lilly's retatrutide in preclinical study

The Korean company reports better weight loss and muscle preservation in animals, with a US trial planned for 2027.

full coverage →obesitypreclinicalglp-1
Seres reports 12 of 15 patients with cancer-treatment-related bowel inflammation improved without immune suppressants

The company plans a prevention study in colitis tied to cancer immunotherapy.

full coverage →microbiomeoncologyclinical-trial
Precigen's treatment has started in over 500 patients for a disease long managed by repeated surgery

The company reports growing uptake of its therapy for recurrent respiratory papillomatosis.

full coverage →cell-therapyclinical
The daily briefTop stories, once a day. Or build your own feed.